US drugmaker Johnson & Johnson said Monday that it will be able to supply 20 million doses of its coronavirus vaccine to the United States by the end of March, assuming it receives clearance from federal regulators.
J&J disclosed the figure in written testimony ahead of its congressional hearing scheduled for Tuesday, which will review the nation’s vaccine supply. Last week, White House officials warned that the first supplies of J & J’s vaccine, which only needs one dose, would be limited.
The company reiterated that it will have the capacity to provide 100 million doses to the United States by the end of June. That supply will help the US government reach its goal of having enough vaccines to inoculate the majority of American adults this year. Internationally, the company aims to produce 1 billion doses during 2021.
Health regulators in the United States continue to review the vaccine’s safety and effectiveness, and are expected to decide this week whether to allow its emergency use. The J&J vaccine would be the first in the United States to require only one dose.
Currently available vaccines developed by Pfizer and Moderna require two doses that must be administered several weeks apart. Executives from both companies and two other vaccine manufacturers will also testify at Tuesday’s hearing.